Biotechnology

Wednesday Aug 18, 2021 - 12:24 pm

InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) Presenting at Emerging Growth Conference

Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables and platform technology solutions to the worldwide life sciences and other key industries, has announced its participation in the Emerging Growth Conference taking place on Aug. 18, 2021. The real-time, interactive investor conference will feature 10 companies, presenting for 15-45 minutes each. PBI's president and CEO, Richard…

Tuesday Aug 17, 2021 - 2:51 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic…

Tuesday Aug 17, 2021 - 11:14 am

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final design of its i/Blue Imaging System(TM) is on target to be demonstrated at the American Urology Association (“AUA”) Annual Meeting in September. In its 116th year, the AUA Annual Meeting is the largest gathering of…

Friday Aug 13, 2021 - 2:32 pm

InvestorNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data…

Friday Aug 13, 2021 - 10:00 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer.…

Thursday Aug 12, 2021 - 1:10 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This…

Wednesday Aug 11, 2021 - 2:16 pm

InvestorNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is…

Wednesday Aug 11, 2021 - 11:03 am

InvestorNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on…

Friday Aug 06, 2021 - 2:20 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Positioned to be at Center Stage of Neurological Diagnostics Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears well-positioned to offer solutions for the growing market need in the post-pandemic world. “As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting,” reads a recent article. As such, the market for BRSF’s innovative products appears…

Friday Aug 06, 2021 - 1:43 pm

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Paving Way for Better Outcomes of Plant-Based Treatments

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is known for its high-quality information and digital health care analytics through which it is positively impacting the future treatment of patients for various medical conditions worldwide. RYAH is partnering with the University of Milan and companies like Medical Kiwi to drive innovation and deliver cutting-edge medical solutions, as well as providing…

Friday Aug 06, 2021 - 12:13 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Poised to Establish New Standard in Bladder Cancer Visualization

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stage and is expected to be completed in 2022, allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. It will…

Tuesday Aug 03, 2021 - 1:07 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s focus on psychedelics, how he got involved with Tryp and…

Friday Jul 30, 2021 - 12:04 pm

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Developing, Delivering New Generation of MedTech Solutions for Brain Diagnostics Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, recently announced its entry into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. The merger is anticipated to expand the market footprint both for Brain Scientific and Piezo Motion, as well as the potential to deliver innovative technologies to high-growth sectors. Dr.…

Wednesday Jul 28, 2021 - 12:10 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the…

Wednesday Jul 28, 2021 - 10:25 am

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at…

Tuesday Jul 27, 2021 - 3:44 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide…

Tuesday Jul 27, 2021 - 11:26 am

InvestorNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Manufacture of Synthetic Ibogaine Moves to Second Stage

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has begun the second stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research. According to the announcement, this stage will focus on assessing the quality of MINDCURE’s synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing. The company…

Friday Jul 23, 2021 - 11:13 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Poised as Key Innovative Leader at Forefront in Neurology Tech

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain…

Friday Jul 23, 2021 - 10:58 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Looking to Unlock Additional Value with Russell 2000 Index Inclusion

CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to be added to the Russell 2000 Index effective June 25. A subset of the Russell 3000 Index, the Russell 2000 Index is a measure of the performance of the small-cap…

Wednesday Jul 21, 2021 - 10:02 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. According to the update, the open-label trial will evaluate the…

Friday Jul 16, 2021 - 1:49 pm

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “While others must wait for outcome…

Friday Jul 16, 2021 - 11:49 am

InvestorNewsBreaks – RYAH Group Inc. (CSE: RYAH) Brings Powerful Capabilities to Modern Clinical Trials

RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics. These provide next-generation capabilities that allow for more control of variables within a clinical setting, which is especially significant in modern cannabis clinical trials. While historical emphasis has largely been centered on potential harmful effects, today’s research teams are exploring the use of cannabis…

Wednesday Jul 14, 2021 - 11:14 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Further Research in Psychedelic Treatment for Mental Health

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize…

Tuesday Jul 13, 2021 - 1:16 pm

InvestorNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free…

Tuesday Jul 13, 2021 - 11:24 am

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class…

Monday Jul 12, 2021 - 9:52 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to…

Friday Jul 09, 2021 - 11:11 am

InvestorNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and…

Friday Jul 09, 2021 - 9:44 am

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will…

Thursday Jul 08, 2021 - 11:05 am

InvestorNewsBreaks – Brain Scientific Inc. (BRSF) Brings Cutting-Edge Tech to the Neurology Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical…

Wednesday Jul 07, 2021 - 1:22 pm

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that…

Wednesday Jul 07, 2021 - 12:15 pm

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered…

Wednesday Jul 07, 2021 - 9:50 am

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp's intellectual property portfolio…

Friday Jul 02, 2021 - 10:39 am

InvestorNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result…

Friday Jul 02, 2021 - 10:24 am

InvestorNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific…

Thursday Jul 01, 2021 - 2:35 pm

InvestorNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth…

Thursday Jul 01, 2021 - 12:37 pm

InvestorNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s…

Thursday Jul 01, 2021 - 12:21 pm

InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. Fluence, a psychedelic therapy educational platform, will provide design and…

Wednesday Jun 30, 2021 - 10:02 am

InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Finalizes Supply Agreement with Two German Companies for COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has inked a master supply agreement with two German diagnostics, testing, and medical logistics companies: Beovita GmbH & Co. KG and Tackleberries GmbH. The two companies run 10 COVID-19 test centers in Berlin. The supply agreement outlines the delivery of approximately 1,000 of XPhyto’s proprietary Covid-ID Lab…

Tuesday Jun 29, 2021 - 10:47 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives FDA Fast Track Status for Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that the U.S. Food and Drug Administration granted Fast Track Designation for Berubicin, the company’s lead investigational drug. The status was received for the company’s evaluation of Berubicin for the treatment of patients with recurrent glioblastoma multiforme (“GBM”).…

Friday Jun 25, 2021 - 10:44 am

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss 2021 FY Results, Provide Business Update

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions